Immuneering Corporation has entered a collaboration with Astellas Pharma to supply its MEK inhibitor, atebimetinib, for two clinical trials targeting pancreatic cancer patients with CLDN18.2-expressing tumors. One trial will test atebimetinib combined with Astellas' CLDN18.2-targeted therapy plus chemotherapy in first-line metastatic patients, while the other will explore a chemotherapy-free regimen for previously treated patients. This partnership aims to evaluate the synergy between atebimetinib and CLDN18.2 therapies to improve treatment outcomes. Immuneering retains global rights to atebimetinib, and Astellas holds rights to its CLDN18.2 programs, with further trial details forthcoming.
Immuneering's collaboration with Astellas on pancreatic cancer clinical trials is the story's focus, with Pluang data showing 91 of 150 Health-sector US stocks rose today. As of Nov 12, 2026 19:11 WIB, notable movers include TAK at USD 21.30 with a 2.21% increase and 100% buy order activity, ALNY at USD 163.03 up 1.99%, and AHCO at USD 7.62 down 2.31% with 100% sell order activity. This snapshot reflects active trading dynamics in the health sector on Pluang.
Evaxion, a clinical-stage TechBio company, has released its financial calendar for 2027, outlining important dates for business updates and financial results. Key events include the full year 2026 results on March 4, the Annual General Meeting on Apr...
CollPlant Biotechnologies will change its Nasdaq ticker from CLGN to OPHI starting November 13, 2026, reflecting its strategic shift toward photonic computing through its subsidiary LightSolver. This move highlights CollPlant's focus on developing Li...
Glider has introduced a global investing platform for tokenized stocks that operates permissionlessly, bypassing the SEC's Tokenized Securities Venues (TSVs) which 50 public companies recently rejected. Backed by major investors like a16z and Coinbas...
BofA Securities raised its price target for Royal Caribbean Group to $365, citing strong booking volumes and the company’s goal of adjusted earnings per share around $20 by 2027. The cruise operator expects 4.5% capacity growth next year and has repo...
Tilray Brands announced that its subsidiaries 10 Barrel Brewing, Widmer Brothers Brewing, and Hop Valley Brewing are now the official craft beer partners of the Portland Trail Blazers. This partnership expands the availability of Oregon craft beers a...
